Inhibition of the CDK1/PDK1/β-catenin signaling axis downregulates CSCs phenotype formation and enhances hepatocellular cancer sensitivity to sorafenib therapy [14]. The gene discussed is CDK1; the disease is hepatocellular carcinoma.